Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

PURPOSE: Antivascular endothelial growth factor (anti-VEGF) therapy is a promising treatment approach for patients with recurrent glioblastoma. This single-arm phase II study evaluated the efficacy of aflibercept (VEGF Trap), a recombinantly produced fusion protein that scavenges both VEGF and place...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: de Groot, John F., Lamborn, Kathleen R., Chang, Susan M., Gilbert, Mark R., Cloughesy, Timothy F., Aldape, Kenneth, Yao, Jun, Jackson, Edward F., Lieberman, Frank, Robins, H. Ian, Mehta, Minesh P., Lassman, Andrew B., DeAngelis, Lisa M., Yung, W.K. Alfred, Chen, Alice, Prados, Michael D., Wen, Patrick Y.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3139373/
https://ncbi.nlm.nih.gov/pubmed/21606416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.1636
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados